New molecular entities had a rough week at the US FDA, as the agency issued a complete response letter for Gilead Sciences, Inc.’s bulevirtide for hepatitis delta virus infection, CytoDyn, Inc. withdrew its BLA for leronlimab in multi-drug resistant HIV, and FDA action on Amicus Therapeutics, Inc.’s cipaglucosidase alfa was deferred due to COVID-19 lockdowns in China.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?